Long-term lecanemab data show increased patient benefit with maintained safety profile
Stockholm, Sweden July 30, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented the latest findings for lecanemab (generic name, brand name: Leqembi®). Three-year data show that lecanemab continues to give increased patient benefit for patients with early Alzheimer’s disease with maintained safety profile. In addition, data from the earliest patient cohort showed that 51% of these patients improved their cognition and function score after three years of treatment. The data was presented at the Alzheimer’s Association International Conference (AAIC) 2024, held